AtriCure Statistics
Total Valuation
AtriCure has a market cap or net worth of $1.46 billion. The enterprise value is $1.37 billion.
Important Dates
The next confirmed earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AtriCure has 50.63 million shares outstanding. The number of shares has increased by 1.67% in one year.
| Current Share Class | 50.63M |
| Shares Outstanding | 50.63M |
| Shares Change (YoY) | +1.67% |
| Shares Change (QoQ) | +1.99% |
| Owned by Insiders (%) | 4.05% |
| Owned by Institutions (%) | 98.26% |
| Float | 48.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 203.84 |
| PS Ratio | 2.73 |
| Forward PS | 2.37 |
| PB Ratio | 3.01 |
| P/TBV Ratio | 6.97 |
| P/FCF Ratio | 30.20 |
| P/OCF Ratio | 25.43 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 123.36, with an EV/FCF ratio of 28.32.
| EV / Earnings | n/a |
| EV / Sales | 2.56 |
| EV / EBITDA | 123.36 |
| EV / EBIT | n/a |
| EV / FCF | 28.32 |
Financial Position
The company has a current ratio of 3.96, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.96 |
| Quick Ratio | 2.87 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 5.85 |
| Debt / FCF | 1.58 |
| Interest Coverage | -1.61 |
Financial Efficiency
Return on equity (ROE) is -2.40% and return on invested capital (ROIC) is -2.34%.
| Return on Equity (ROE) | -2.40% |
| Return on Assets (ROA) | -0.93% |
| Return on Invested Capital (ROIC) | -2.34% |
| Return on Capital Employed (ROCE) | -1.65% |
| Weighted Average Cost of Capital (WACC) | 11.84% |
| Revenue Per Employee | $395,947 |
| Profits Per Employee | -$8,480 |
| Employee Count | 1,350 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 1.74 |
Taxes
In the past 12 months, AtriCure has paid $1.29 million in taxes.
| Income Tax | 1.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.22% in the last 52 weeks. The beta is 1.43, so AtriCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | -10.22% |
| 50-Day Moving Average | 30.49 |
| 200-Day Moving Average | 34.72 |
| Relative Strength Index (RSI) | 44.49 |
| Average Volume (20 Days) | 581,608 |
Short Selling Information
The latest short interest is 3.54 million, so 6.99% of the outstanding shares have been sold short.
| Short Interest | 3.54M |
| Short Previous Month | 3.41M |
| Short % of Shares Out | 6.99% |
| Short % of Float | 7.29% |
| Short Ratio (days to cover) | 6.29 |
Income Statement
In the last 12 months, AtriCure had revenue of $534.53 million and -$11.45 million in losses. Loss per share was -$0.24.
| Revenue | 534.53M |
| Gross Profit | 400.78M |
| Operating Income | -9.45M |
| Pretax Income | -10.16M |
| Net Income | -11.45M |
| EBITDA | 11.08M |
| EBIT | -9.45M |
| Loss Per Share | -$0.24 |
Full Income StatementBalance Sheet
The company has $167.43 million in cash and $76.42 million in debt, with a net cash position of $91.01 million or $1.80 per share.
| Cash & Cash Equivalents | 167.43M |
| Total Debt | 76.42M |
| Net Cash | 91.01M |
| Net Cash Per Share | $1.80 |
| Equity (Book Value) | 491.94M |
| Book Value Per Share | 9.88 |
| Working Capital | 241.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $57.33 million and capital expenditures -$9.05 million, giving a free cash flow of $48.28 million.
| Operating Cash Flow | 57.33M |
| Capital Expenditures | -9.05M |
| Depreciation & Amortization | 20.53M |
| Net Borrowing | 5.05M |
| Free Cash Flow | 48.28M |
| FCF Per Share | $0.95 |
Full Cash Flow StatementMargins
Gross margin is 74.98%, with operating and profit margins of -1.77% and -2.14%.
| Gross Margin | 74.98% |
| Operating Margin | -1.77% |
| Pretax Margin | -1.90% |
| Profit Margin | -2.14% |
| EBITDA Margin | 2.07% |
| EBIT Margin | -1.77% |
| FCF Margin | 9.03% |
Dividends & Yields
AtriCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.67% |
| Shareholder Yield | -1.67% |
| Earnings Yield | -0.79% |
| FCF Yield | 3.31% |
Analyst Forecast
The average price target for AtriCure is $51.17, which is 77.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $51.17 |
| Price Target Difference | 77.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 13.48% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AtriCure has an Altman Z-Score of 6.75 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.75 |
| Piotroski F-Score | 5 |
